The Latest Breaking News from Johnson & Johnson (

CNBC host Jim Cramer has become more cautious toward AI and data center stocks after seeing increasing insider selling and borrowing activity. 

RFK Jr signed order withdrawing rule that would mandate testing for the cancer-linked toxin in talc-based makeup

Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

Johnson Johnson (NYSE:JNJ) stock has surged almost 42.9% in the year to date, approximately 35% in 6 months, and 8.6% in one month.

A powerful rotation into healthcare is taking shape across global markets, with investors pouring money into sector ETFs at one of the fastest clips this year. What started as a cautious move toward defensive stability has quickly morphed into a broader enthusiasm for biotech, pharma and healthcare-services names – helped…

Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio

On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s (NYSE:KVUE) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.

Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability across multiple sectors.

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common cancer in women

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.